Comparing two strengths of Nepafenac eyedrops (0.3 and 0.1 percent) to prevent inflammation after pan retinal photocoagulation in diabetic retinopathy

Comparative efficacy of Nepafenac 0.3 percent once daily versus Nepafenac 0.1 percent thrice daily eyedrops in preventing macular edema following pan retinal photocoagulation in diabetic retinopathy. - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/09/094432

Enrollment

Registered

2025-09-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H358- Other specified retinal disorders

Interventions

Intervention1: Nil: Nil Intervention2: Nepafenac 0.1% eyedrop (Nepalact): Dose:0.1% Frequency:3 times per day (at 8am-2pm-8pm by attendant) Route: Topical Duration: 6 weeks Control Intervention1: Nep

Eligibility

Inclusion criteria

Inclusion criteria: 1.All cases undergoing Pan retinal photocoagulation with proliferative Diabetic Retinopathy 2.Central Macular Thickness less than 300 microns

Exclusion criteria

Exclusion criteria: 1.Dry eye 2.Prior history of intravitreal injections or focal laser less than 6 months ago 3.Presence of incomplete Pan retinal photocoagulation 4.Any vitreo-retinal interface pathology like epiretinal membrane or vitreo-macular traction 5.Patients who lost follow up

Design outcomes

Primary

Measure	Time frame
visual Acquity (by LogMAR chart)Timepoint: after PRP1, after PRP2, after PRP3 and 1 month, 2 months and 3 months after PRP3.	—

Secondary

Measure	Time frame
Central Macular Thickness (Documented by OCT)Timepoint: after PRP1, after PRP2, after PRP3 and 1 month, 2 months and 3 months after PRP3.	—

Countries

India

Contacts

Public ContactDr Supriya Pandharinath Dhondge

Sankara Eye Hospital ,Guntur ,Andhra Pradesh

drjayamadhury@gmail.com09885335077

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Sep 19, 2026